Holen Sie sich die Stockscreener-App
31.88
3.57%
-1.18
Handel nachbörslich:
31.88
Schlusskurs vom Vortag:
$33.06
Offen:
$33.06
24-Stunden-Volumen:
712.73K
Relative Volume:
0.86
Marktkapitalisierung:
$1.90B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.11M
KGV:
-14.66
EPS:
-2.1745
Netto-Cashflow:
$-102.47M
1W Leistung:
+4.08%
1M Leistung:
-0.19%
6M Leistung:
+3.44%
1J Leistung:
+191.67%
1-Tages-Spanne:
$31.12
$33.06
1-Wochen-Bereich:
$30.16
$33.26
52-Wochen-Spanne:
$9.96
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
31.88 | 1.85B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Guggenheim | Buy |
| 2026-04-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-10-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-08-15 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TYRA|Tyra Biosciences Inc|Price:31.802|Chg%:+1.172 - TradingKey
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TYRA|Tyra Biosciences Inc|Price:31.060|Chg%:+0.430 - TradingKey
TradingKey - TradingKey
Tyra Biosciences, Inc. Revenue Breakdown – NASDAQ:TYRA - TradingView
Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC - Traders Union
Tyra Biosciences (TYRA) Q4 2025 earnings summary - Quartr
Tyra Biosciences (TYRA) Jefferies London Healthcare Conference 2025 Summary - Quartr
Tyra Biosciences (TYRA) Proxy filing Summary - Quartr
Tyra Biosciences pursues new treatment strategies for urologic cancers - Traders Union
Behavioral Patterns of TYRA and Institutional Flows - Stock Traders Daily
Tyra Biosciences (TYRA) Bank of America Global Healthcare Conference 2026 Summary - Quartr
Tyra Biosciences (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D Investment; Stock Dips SlightlyProfit Guidance Range - dars.gov.et
Price to earnings forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
Enterprise value to EBIT forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Price to sales forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Tyra Biosciences Inc. (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline Progress Drives Positive SentimentPost-Earnings Drift - dars.gov.et
Non Muscle Invasive Bladder Cancer Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Enterprise value to EBITDA forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Insider Monkey
Bladder Cancer Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Tyra Biosciences (TYRA) Holds Slight Gains as Resistance Level NearsWeekly Profile - dars.gov.et
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark - marketscreener.com
TYRA Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineLow Growth Earnings - dars.gov.et
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark - marketscreener.com
(TYRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 2500 Value Benchmark - marketscreener.com
10 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Tyra Biosciences, Inc.(NasdaqGS:TYRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 2000 Value Benchmark - marketscreener.com
Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com - Investing.com Nigeria
Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks - Moomoo
TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026 - Stock Titan
Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA) - TradingView
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In? - Sahm
TYRA Forecast — Price Target — Prediction for 2027 - TradingView
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
JonesTrading Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $56 - 富途牛牛
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight - Yahoo Finance
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):